Orkambi 100 MG-125 MG tablet UD 28S
Ended Awarded Last action
- Contract number
- SPE2DR26FCHW9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,529
Award facts
- Contract value 100% obligated
- $17,528.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $17,528.94 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Orkambi 100 mg-125 mg tablets in unit dose packaging (28-count). This firm fixed-price delivery order, issued on January 22, 2026, with an ultimate completion date of January 23, 2026, represents a tactical pharmaceutical fulfillment executed without set-aside designation, demonstrating the vendor's competitive standing in unrestricted federal procurement. The order is fulfilled under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to support recurring medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has maintained active federal contracting relationships with the Defense Logistics Agency's Medical Supply Chain division since 2001 and has demonstrated substantial capability across a comprehensive pharmaceutical product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. As a regional prime vendor contractor within the broader PPV-G GEN V framework—structured with a 30-month base period and three 30-month option periods extending through December 31, 2036—the company serves as a critical supplier supporting the diverse pharmaceutical requirements of the military medical system. No subcontractors were identified in the award documentation for this delivery order.
Quick answers
Who was awarded contract SPE2DR26FCHW9?
SPE2DR26FCHW9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FCHW9 worth?
The government has obligated $17,529 on SPE2DR26FCHW9.
Is contract SPE2DR26FCHW9 an order under another contract?
Yes. SPE2DR26FCHW9 is a delivery order under SPE2DR25D9113, an indefinite delivery contract.
Was contract SPE2DR26FCHW9 competed?
The extent of competition for SPE2DR26FCHW9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award